1. Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. (November 2021) Authors: Pinato, David J.; Marron, Thomas U.; Mishra-Kalyani, Pallavi Shruti; Gong, Yutao; Wei, Guo; Szafron, David; Sharon, Elad; Saeed, Anwaar; Jun, Tomi; Dharmapuri, Sirish; Naqash, Abdul R.; Peeraphatdit, Thoetchai; Gampa, Anuhya; Wang, Yinghong; Khan, Uqba; Muzaffar, Mahvish; Navaid, Musharraf; Lee, ... Journal: European journal of cancer Issue: Volume 157(2021) Page Start: 140 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Systematic Review of PD‐1/PD‐L1 Inhibitors in Oncology: From Personalized Medicine to Public Health. (27th July 2021) Authors: Chang, Elaine; Pelosof, Lorraine; Lemery, Steven; Gong, Yutao; Goldberg, Kirsten B.; Farrell, Ann T.; Keegan, Patricia; Veeraraghavan, Janaki; Wei, Guo; Blumenthal, Gideon M.; Amiri‐Kordestani, Laleh; Singh, Harpreet; Fashoyin‐Aje, Lola; Gormley, Nicole; Kluetz, Paul G.; Pazdur, Richard; Beaver, ... Journal: Oncologist Issue: Volume 26:Number 10(2021) Page Start: e1786 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib. (10th June 2021) Authors: Saung, May Tun; Pelosof, Lorraine; Casak, Sandra; Donoghue, Martha; Lemery, Steven; Yuan, Mengdie; Rodriguez, Lisa; Schotland, Peter; Chuk, Meredith; Davis, Gina; Goldberg, Kirsten B.; Theoret, Marc R.; Pazdur, Richard; Fashoyin-Aje, Lola Journal: Oncologist Issue: Volume 26:Number 9(2021) Page Start: 797 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health. (27th July 2021) Authors: Chang, Elaine; Pelosof, Lorraine; Lemery, Steven; Gong, Yutao; Goldberg, Kirsten B.; Farrell, Ann T.; Keegan, Patricia; Veeraraghavan, Janaki; Wei, Guo; Blumenthal, Gideon M.; Amiri-Kordestani, Laleh; Singh, Harpreet; Fashoyin-Aje, Lola; Gormley, Nicole; Kluetz, Paul G.; Pazdur, Richard; Beaver, ... Journal: Oncologist Issue: Volume 26:Number 10(2021) Page Start: e1786 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Benefit‐Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration‐Positive, Metastatic Non‐Small Cell Lung Cancer. (21st June 2016) Authors: Kazandjian, Dickran; Blumenthal, Gideon M.; Luo, Lola; He, Kun; Fran, Ingrid; Lemery, Steven; Pazdur, Richard Journal: Oncologist Issue: Volume 21:Number 8(2016) Page Start: 974 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer. (21st June 2016) Authors: Kazandjian, Dickran; Blumenthal, Gideon M.; Luo, Lola; He, Kun; Fran, Ingrid; Lemery, Steven; Pazdur, Richard Journal: Oncologist Issue: Volume 21:Number 8(2016) Page Start: 974 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. FDA Accelerated Approval of Pembrolizumab for Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma. (28th April 2020) Authors: Bradford, Diana; Demko, Suzanne; Jin, Susan; Mishra‐Kalyani, Pallavi; Beckles, Aaliyah R.; Goldberg, Kirsten B.; Lemery, Steven; Ward, Ashley; Keegan, Patricia; Pazdur, Richard Journal: Oncologist Issue: Volume 25:Number 7(2020) Page Start: e1077 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Benefit–Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine‐ and Platinum‐Based Chemotherapy. (11th January 2021) Authors: Pelosof, Lorraine; Saung, May Tun; Donoghue, Martha; Casak, Sandra; Mushti, Sirisha; Cheng, Joyce; Jiang, Xiling; Liu, Jiang; Zhao, Hong; Khazraee, Maryam; Goldberg, Kirsten B.; Theoret, Marc; Lemery, Steven; Pazdur, Richard; Fashoyin‐Aje, Lola Journal: Oncologist Issue: Volume 26:Number 4(2021) Page Start: 318 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib. (10th June 2021) Authors: Saung, May Tun; Pelosof, Lorraine; Casak, Sandra; Donoghue, Martha; Lemery, Steven; Yuan, Mengdie; Rodriguez, Lisa; Schotland, Peter; Chuk, Meredith; Davis, Gina; Goldberg, Kirsten B.; Theoret, Marc R.; Pazdur, Richard; Fashoyin‐Aje, Lola Journal: Oncologist Issue: Volume 26:Number 9(2021) Page Start: 797 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Benefit‐Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib. (31st January 2018) Authors: Pelosof, Lorraine; Lemery, Steven; Casak, Sandra; Jiang, Xiaoping; Rodriguez, Lisa; Pierre, Vadryn; Bi, Youwei; Liu, Jiang; Zirkelbach, Jeanne Fourie; Patel, Anuja; Goldberg, Kirsten B.; McKee, Amy E.; Keegan, Patricia; Pazdur, Richard Journal: Oncologist Issue: Volume 23:Number 4(2018) Page Start: 496 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗